Johnson & Johnson riceve il parere positivo del CHMP per RYBREVANT®▼ (amivantamab) in combinazione con la chemioterapia per il trattamento di prima linea di pazienti con carcinoma polmonare non a piccole cellule in stadio avanzato con mutazioni attivanti da inserzione nell’esone 20 dell’EGFR
April 30, 2024 12:20 ET
|
Janssen Cilag International NV
Il parere positivo del CHMP stabilisce che amivantamab rappresenta una nuova opzione, nonché il primo anticorpo bispecifico EGFR-MET completamente umano, nel trattamento di prima linea del NSCLC con...
Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
April 26, 2024 07:55 ET
|
Janssen Cilag International NV
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC ...
CARVYKTI®▼ (Ciltacabtagen Autoleucel; Cilta-cel) ist die erste von der Europäischen Kommission zugelassene BCMA-gerichtete Therapie für die Behandlung von Patienten mit rezidiviertem und refraktärem Multiplem Myelom, die mindestens eine vorherige Therapielinie erhalten haben
April 24, 2024 11:58 ET
|
Janssen Cilag International NV
Die erweiterte Indikation für diese einmalig verabreichte Infusion kann Patienten mit Multiplem Myelom bereits nach dem ersten Rückfall eine behandlungsfreie Zeit ermöglichen1 Die Zulassung wurde...
CARVYKTI®▼ (ciltacabtagén autoleucel; cilta-cel) es el primer tratamiento dirigido a BCMA aprobado por la Comisión Europea para pacientes con mieloma múltiple en recaída y refractario que hayan recibido al menos una línea previa de tratamiento
April 24, 2024 11:57 ET
|
Janssen Cilag International NV
La indicación ampliada de esta dosis única para perfusión puede ofrecer a los pacientes de mieloma múltiple un periodo libre de tratamiento desde la primera recaída1 La aprobación se basa en los...
CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) is the first BCMA-targeted treatment approved by the European Commission for patients with relapsed and refractory multiple myeloma who have received at least one prior line of therapy
April 22, 2024 06:41 ET
|
Janssen Cilag International NV
Expanded indication for this one-time infusion may provide patients with a potential period away from their multiple myeloma treatment as early as first relapse1 Approval is based on results...
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
March 06, 2024 08:53 ET
|
Janssen Cilag International NV
Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk of progression or death, compared to...
Janssen recibe la opinión positiva del CHMP para CARVYKTI®▼ (ciltacabtagén autoleucel; cilta-cel) para el tratamiento en líneas más tempranas de mieloma múltiple en recaída y refractario
February 28, 2024 14:25 ET
|
Janssen Pharmaceutica NV
Los resultados del estudio de fase 3 CARTITUDE-4, que respaldaron la recomendación del CHMP, demostraron que cilta-cel podría ofrecer un beneficio significativo a los pacientes en líneas de...
Janssen reçoit un avis favorable de la part du CMUH pour CARVYKTI®▼ (ciltacabtagène autoleucel ; cilta-cel) dans le traitement du myélome multiple en rechute et réfractaire en premières lignes
February 28, 2024 14:21 ET
|
Janssen Pharmaceutica NV
Les résultats de l’étude de phase III CARTITUDE-4, qui étayent la recommandation du CMUH, ont démontré que le cilta-cel avait le potentiel d’offrir un bénéfice significatif aux patients en premières...
Janssen erhält positives CHMP-Gutachten für CARVYKTI®▼ (Ciltacabtagen Autoleucel; Cilta-cel) zur Behandlung früherer Stadien des rezidivierten und refraktären Multiplen Myeloms
February 28, 2024 14:18 ET
|
Janssen EMEA
Die Ergebnisse der Phase-III-Studie CARTITUDE-4, die die CHMP-Empfehlung unterstützen, zeigten das Potenzial von Cilta-cel, für Patienten in früheren Therapielinien einen erheblichen Nutzen zu bieten1...
Janssen Receives Positive CHMP Opinion for CARVYKTI®▼ (ciltacabtagene autoleucel; cilta-cel) for Treatment in Earlier Lines of Relapsed and Refractory Multiple Myeloma
February 23, 2024 06:22 ET
|
Janssen Pharmaceutica NV
Results from the Phase 3 CARTITUDE-4 study, which supported the CHMP recommendation, showed that cilta-cel has the potential to offer significant benefit to patients in earlier lines of treatment1 ...